Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Generation Bio Co (GBIO) USD0.0001

Sell:$25.88 Buy:$26.02 Change: $0.39 (1.53%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.39 (1.53%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.39 (1.53%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Generation Bio Co. is a genetic medicines company. The Company is developing a class of gene therapy utilizing its non-viral gene therapy platform to provide durable, redosable treatments for patients living with rare and prevalent diseases. The Company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The Company is developing gene therapies to provide targeted delivery of genetic payloads that include multiple genes to a range of tissues of diseases. The Company is also engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The Company is a preclinical stage company and have not identified a product candidate.

Contact details

United States
+1 (857) 5295908

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.44 billion
Shares in issue:
56.78 million
United States
US dollar

Key personnel

  • Cameron Mcdonough
    President, Chief Executive Officer, Director
  • Matthew Norkunas
    Chief Financial Officer
  • Mark Angelino
    Chief Operating Officer
  • Matthew Stanton
    Chief Scientific Officer
  • Douglas Kerr
    Chief Medical Officer
  • Tracy Zimmermann
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.